Publicaciones en colaboración con investigadores/as de University of Erlangen-Nuremberg (1)

2017

  1. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

    The Lancet, Vol. 390, Núm. 10102, pp. 1585-1594